ClinicalTrials.gg
CompletedNCT00598702Updated May 10, 2017Results posted

Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients

A Phase 3 interventional study of IV Acetaminophen in Pain and Fever, sponsored by Mallinckrodt. Completed at 14 sites in United States. Open to participants aged 37 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
37 Weeks to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
63rd of 137
100 · median 95
Started
2008
with 7 others
Phase 3
22 of 137
none open now
Registered
21st of 137
by date
Lead sponsor
6 of 137
Mallinckrodt

Among the 137 studies testing acetaminophen in Pain, this one is the 63rd largest by enrollment, is one of 8 that started in 2008, is one of 22 in phase 3, and was the 21st registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 37 Weeks to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

Intravenous acetaminophen (IVAPAP) is safe in repeated dose, multi-day clinical use when administered at a daily dose of 40 to 75 mg/kg body weight

Read the detailed description

To assess the safety of intravenous acetaminophen (IV APAP) when used over one or more days for the treatment of acute pain or fever in pediatric (neonates, infants, children and adolescents) inpatients who are unable to take anything by mouth (NPO), require or would benefit from IV treatment, or are willing and able to stay on IVAPAP therapy for 1 to 7 days.

03

Conditions studied

  • Pain
  • Fever

Browse trials for

04

Who can participate

Ages eligible
37 Weeks to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The Subject's Parent or Guardian must provide written , with Subject assent where appropriate, prior to the Subject's participation in the Study.
  • Be less than 17 years of age and older than 37 weeks post conception
  • Anticipated by the Investigator to require multi-day (minimum of one day) use of intravenous (IV) treatment either because of a having a status of nothing by mouth (NPO) or a medical condition that makes oral intake difficult or be willing to undergo at least 5 days of treatment with IV acetaminophen for the treatment of pain or fever
  • Have the ability to read and understand the Study procedures and have the ability to communicate meaningfully with the Study Investigator and staff (if the Subject is of preverbal age or cannot read or communicate meaningfully, then the Subject's Parent or Guardian must meet this criterion)
  • If a female of child bearing potential, have a negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Has significant medical disease(s), laboratory abnormalities or condition(s) that in the Investigator's judgment could compromise the Subject's welfare, ability to communicate with the Study staff, complete Study activities, or would otherwise contraindicate Study participation
  • Has known or to receiving IV acetaminophen or the inactive ingredients () of IV acetaminophen
  • Has impaired liver function, e.g. (ALT) greater than or equal to 3 times the (ULN), greater than or equal to 3 times ULN, known active hepatic disease (e.g., hepatitis), evidence of chronic liver disease or other condition affecting the liver (e.g., alcoholism as defined by the , Fourth Edition (DSM-IV), cirrhosis, or chronic hepatitis) that may suggest the potential for an increased susceptibility to hepatic toxicity with IV acetaminophen exposure
  • Has participated in an interventional clinical Study ( or marketed product) within 30 days of Study entry
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    IV Acetaminophen

    40 to 75 mg/kg/day every 4 to 6 hours

    Drug: IV Acetaminophen

Interventions

  • Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose

    Also known as: IV APAP, APAP

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)

    A TEAE is defined as an adverse event that starts on or after the start of study medication.

    Time frame: First dose to end of treatment period

  2. Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event

    A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV APAP that; * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

    Time frame: First dose to 30 days after last dose

Secondary outcomes

  1. Subject's (Parent/Guardian) Global Evaluation of Study Treatment

    Subject's (parent/guardian) was asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair, 2=good, 3= excellent).

    Time frame: Day 0 to Day 5, Day 7 or Early Termination from study

  2. Physician's Global Assessment of Study Treatment

    Physicians were asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair,2=good, 3= excellent).

    Time frame: End of study or Early Termination

07

Results

Posted Jan 6, 2011
Limitations and caveats
The original protocol required 50 subjects that completed 5 days of treatment. With protocol amendment 2, the criteria for enrollment/completion was reduced to 1 day of treatment. Subjects were required to have a minimum of 3 IV APAP doses per day.

Participant flow

Multi-center study conducted in the United States from 19 Mar 2008 - 24Dec 2008

Participant flow — Overall Study
MilestoneNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Started1373394214
Completed1152563004
Not completed022831210
Withdrew: Other02000100
Withdrew: Early discharge from hospital002501010
Withdrew: Adverse event00010000
Withdrew: Withdrawal by subject00011000
Withdrew: Physician decision00001000
Withdrew: Dose limiting toxicity00011100

Outcome measures

SecondarySubject's (Parent/Guardian) Global Evaluation of Study Treatment

Subject's (parent/guardian) was asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair, 2=good, 3= excellent).

Time frame:
Day 0 to Day 5, Day 7 or Early Termination from study
Reported as:
Number · participants
Subject's (Parent/Guardian) Global Evaluation of Study Treatment
participantsNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Poor00000000
Fair00001200
Good0311131701
Excellent1061752312
Missing00050001
PrimaryNumber of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)

A TEAE is defined as an adverse event that starts on or after the start of study medication.

Time frame:
First dose to end of treatment period
Reported as:
Number · Subjects
Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)
SubjectsNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)1152593502
SecondaryPhysician's Global Assessment of Study Treatment

Physicians were asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair,2=good, 3= excellent).

Time frame:
End of study or Early Termination
Reported as:
Number · participants
Physician's Global Assessment of Study Treatment
participantsNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Poor00000000
Fair00000100
Good0211541601
Excellent1161352512
Missing00050001
PrimaryNumber of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event

A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV APAP that; * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

Time frame:
First dose to 30 days after last dose
Reported as:
Number · Subjects
Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event
SubjectsNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event110132301

Adverse events

Collected over Non-serious treatment emergent adverse events (TEAEs) were collected from the initiation of treatment with study medication to the end of the patient's treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h—1/1 (100%)1/1 (100%)
Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h—1/3 (33.3%)1/3 (33.3%)
Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h—0/7 (0%)5/7 (71.4%)
Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h—13/33 (39.4%)24/33 (72.7%)
Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h—2/9 (22.2%)9/9 (100%)
Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h—3/42 (7.1%)33/42 (78.6%)
Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h—0/1 (0%)0/1 (0%)
Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h—1/4 (25%)2/4 (50%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Congenital MegacolonCongenital, familial and genetic disorders1/10/30/70/330/90/420/10/4
Respiratory failureRespiratory, thoracic and mediastinal disorders0/11/30/72/330/90/420/10/4
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders0/10/30/71/330/90/420/11/4
HeadacheNervous system disorders0/10/30/70/331/90/420/10/4
HepatotoxicityHepatobiliary disorders0/10/30/70/331/90/420/10/4
ChylothoraxRespiratory, thoracic and mediastinal disorders0/10/30/72/330/90/420/10/4
Hepatic enzyme increasedInvestigations0/10/30/72/330/91/420/10/4
Wound InfectionInfections and infestations0/10/30/72/330/90/420/10/4
Abdominal abscessInfections and infestations0/10/30/71/330/90/420/10/4
Diaphragmatic disorderRespiratory, thoracic and mediastinal disorders0/10/30/71/330/90/420/10/4
Most frequent other events
Showing 10 of 53
Most frequent other events
EventNeonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h
Skin irritationSkin and subcutaneous tissue disorders1/10/30/70/330/90/420/10/4
NauseaGastrointestinal disorders0/10/33/76/335/917/420/10/4
AgitationPsychiatric disorders0/10/30/73/330/90/420/12/4
WheezingRespiratory, thoracic and mediastinal disorders0/10/30/71/330/90/420/12/4
PruritisSkin and subcutaneous tissue disorders0/10/32/75/334/94/420/10/4
VomitingGastrointestinal disorders0/10/32/77/334/910/420/11/4
AnemiaBlood and lymphatic system disorders0/11/31/72/330/92/420/10/4
ConstipationGastrointestinal disorders0/10/30/711/332/910/420/11/4
HeadacheNervous system disorders0/10/30/71/333/94/420/10/4
Pleural effusionRespiratory, thoracic and mediastinal disorders0/11/30/70/330/91/420/10/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6hTotal
<=18 years1373394214100
Between 18 and 65 years000000000
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8hInfants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6hChildren (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4hChildren (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6hAdolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4hAdolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6hInfants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4hInfants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6hTotal
Female025176290362
Male112163131138
08

Study locations

14 sites
  • Lucile Salter Packard Children's Hospital at Stanford
    Stanford, California 94305, United States
  • Alfred Dupont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's National Medical Center
    Washington, DC, District of Columbia 20010, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan Ann Arbor
    Ann Arbor, Michigan 48109, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • SUNY Stony Brook
    Stony Brook, New York 11794, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Houston Neonatal-Perinatal Physicians
    Bellaire, Texas 77401, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 1 month after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2008
First posted
Jan 22, 2008
Start
Jan 2008
Primary completionActual
Dec 2008
CompletionActual
Jan 2009
Results delay requested
Apr 3, 2009
Results first posted
Jan 6, 2011
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00598702
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jan 22, 2008
Start date
Jan 2008
Primary completion
Dec 2008
Completion
Jan 2009
Results posted
Jan 6, 2011
Last update
May 10, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion